Semaglutide activates GLP-1 receptors in heart tissue and blood vessels, reducing inflammation, lowering blood pressure, and improving blood sugar control independent of weight loss
First, GLP-1RA can activate the first messenger adenylate cyclase (AC) after binding to the receptor, which stimulates an increase in the secretion level of the intracellular second messenger cyclic adenosine phosphate (cAMP) and subsequently activates the intracellular secondary messenger protein kinase A (PKA) (48)
The steady-state factor: why weeks 4 through 5 are the real turning point This is where the pharmacology gets important
GLP-1R agonists also demonstrate neuroprotective effects, including reduction of neuroinflammation, oxidative stress, and neuronal apoptosis, with emerging evidence for benefit in neurodegenerative diseases such as Parkinsons and Alzheimers disease [75, 76]